A constitutively activated form of the p110β isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 24, 2010, Pages 11002-11007

  Lee, Sang Hyun ^a   Poulogiannis, George ^b   Pyne, Saumyadipta ^a   Jia, Shidong ^a   Zou, Lihua ^a   Signoretti, Sabina ^a   Loda, Massimo ^a   Cantley, Lewis Clayton ^b   Roberts, Thomas M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; P110BETA PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TRANSGENE; TUMOR MODEL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AGE FACTORS; ANIMALS; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GENES, MYC; HUMANS; MALE; METAPLASIA; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NF-KAPPA B; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY;

MURINAE; MUS;

EID: 77954641960     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1005642107     Document Type: Article

References (52)

1. Suzuki H, et al. (1998) Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58:204-209. (Pubitemid 28047054)
2. Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606-619. (Pubitemid 44100518)
3. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11:329-341.
4. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL (1999) Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem 274:10963-10968.
5. Bi L, Okabe I, Bernard DJ, Nussbaum RL (2002) Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome 13:169-172. (Pubitemid 34185317)
6. Denley A, Kang S, Karst U, Vogt PK (2008) Oncogenic signaling of class I PI3K isoforms. Oncogene 27:2561-2574. (Pubitemid 351550883)
7. Zhao JJ, et al. (2005) The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 102:18443-18448.
8. Samuels Y, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554. (Pubitemid 38541907)
9. Brugge J, Hung MC, Mills GB (2007) A new mutational AKTivation in the PI3K pathway. Cancer Cell 12:104-107. (Pubitemid 47199129)
10. Knight ZA, et al. (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125:733-747.
11. Guillermet-Guibert J, et al. (2008) The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci USA 105:8292-8297.
12. Jia S, et al. (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454:776-779.
13. Ciraolo E, et al. (2008) Phosphoinositide 3-kinase p110beta activity: Key role in metabolism and mammary gland cancer but not development. Sci Signal 1:ra3.
14. Ciraolo E, et al. (2010) Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility. Mol Biol Cell 21:704-711.
15. Canobbio I, et al. (2009) Genetic evidence for a predominant role of PI3Kbeta catalytic activity in ITAM- and integrin-mediated signaling in platelets. Blood 114:2193-2196.
16. Wang SI, Parsons R, Ittmann M (1998) Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 4:811-815. (Pubitemid 28193582)
17. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP (1998) Pten is essential for embryonic development and tumour suppression. Nat Genet 19:348-355. (Pubitemid 28357906)
18. Ma X, et al. (2005) Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 65:5730-5739.
19. Trotman LC, et al. (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol 1:E59.
20. Wang S, et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209-221.
21. Ratnacaram CK, et al. (2008) Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc Natl Acad Sci USA 105:2521-2526.
22. Zhang J, Thomas TZ, Kasper S, Matusik RJ (2000) A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 141:4698-4710. (Pubitemid 32055150)
23. Scherl A, Li JF, Cardiff RD, Schreiber-Agus N (2004) Prostatic intraepithelial neoplasia and intestinal metaplasia in prostates of probasin-RAS transgenic mice. Prostate 59:448-459. (Pubitemid 38661813)
24. Zhong C, Saribekyan G, Liao CP, Cohen MB, Roy-Burman P (2006) Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Res 66:2188-2194.
25. Kurita T, Medina RT, Mills AA, Cunha GR (2004) Role of p63 and basal cells in the prostate. Development 131:4955-4964. (Pubitemid 39485353)
26. Signoretti S, et al. (2005) p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci USA 102:11355-11360.
27. Majumder PK, et al. (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594-601.
28. Yamada T (1999) Serum amyloid A (SAA): A concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 37:381-388.
29. Katz JP, et al. (2002) The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon. Development 129:2619-2628.
30. Majumder PK, et al. (2003) Prostate intraepithelial neoplasia induced by prostate restricted Akt activation:Tthe MPAKT model. Proc Natl Acad Sci USA 100:7841-7846.
31. Lapointe J, et al. (2007) Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 67:8504-8510. (Pubitemid 47437424)
32. Sweeney C, et al. (2004) Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 10:5501-5507.
33. Ozes ON, et al. (1999) NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401:82-85.
34. Romashkova JA, Makarov SS (1999) NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401:86-90.
35. Bai D, Ueno L, Vogt PK (2009) Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer 125:2863-2870.
36. LaTulippe E, et al. (2002) Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62:4499-4506. (Pubitemid 34827314)
37. Yu YP, et al. (2004) Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22:2790-2799.
38. Varambally S, et al. (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8:393-406.
39. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL (2004) Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113: 913-923.
40. Engelman JA, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351-1356.
41. Zhu Q, et al. (2008) Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 27:4569-4579.
42. Wee S, et al. (2008) PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA 105:13057-13062.
43. Delhase M, Li N, Karin M (2000) Kinase regulation in inflammatory response. Nature 406:367-368.
44. Shen WH, et al. (2007) Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128:157-170.
45. Lemmon MA (2008) Membrane recognition by phospholipid-binding domains. Nat Rev Mol Cell Biol 9:99-111.
46. Carver BS, Pandolfi PP (2006) Mouse modeling in oncologic preclinical and translational research. Clin Cancer Res 12:5305-5311.
47. Garraway IP, Seligson D, Said J, Horvath S, Reiter RE (2004) Trefoil factor 3 is overexpressed in human prostate cancer. Prostate 61:209-214.
48. Vestergaard EM, Borre M, Poulsen SS, Nexø E, Tørring N (2006) Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Clin Cancer Res 12: 807-812.
49. Marqués M, et al. (2009) Specific function of phosphoinositide 3-kinase beta in the control of DNA replication. Proc Natl Acad Sci USA 106:7525-7530.
50. Ellwood-Yen K, et al. (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4:223-238.
51. Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49-54.
52. van 't Veer LJ, et al. (2003) Expression profiling predicts outcome in breast cancer. Breast Cancer Res 5:57-58.